Limited Local Clinical Trials for the New Cancer Treatment Technology Karanahan for Patients with Advanced Breast Cancer

Veronika A Markina; Anastasia S Proskurina; Vera S Ruzanova; Genrikh S Ritter; Evgeniya V Dolgova; Svetlana S Kirikovich; Evgeniy V Levites; Sofya G Oshihmina; Yaroslav R Efremov; Eugene I Vereschagin; Olga Y Leplina; Alexandr A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey V Sidorov; Sergey S Bogachev

doi:10.20944/preprints202409.2002.v1

Preprint Article Version 1 This version is not peer-reviewed

Version 1 : Received: 25 September 2024 / Approved: 25 September 2024 / Online: 25 September 2024 (12:01:00 CEST)

(1) Background: Multi-year research into the synergistic effect of cyclophosphamide and complex composite double-stranded DNA preparation (DNAmix) has made it possible to develop the novel Karanahan technology for treating malignant tumors, which is based on the eradication of cancer stem cells; (2) Methods: Pilot clinical trials for Karanahan technology were conducted in 12 patients with advanced stage IV breast cancer; (3) Results: The findings indicate that the analyzed treatment regimen ensures a local positive therapeutic response, significantly increases patient survival time, and activates the adaptive antitumor immune response. Adjustment of the basic regimen of Karanahan technology has been developed, which consists of increasing the dose of the DNAmix complex composite double stranded DNA preparation and its lymphotropic administration to the main lymph depots simultaneously with intratumoral injection; (4) Conclusions: Karanahan technology has a promising therapeutic potential in the treatment of inoperable stage IV breast cancer.

breast cancer; cyclophosphamide; double-stranded DNA; palliative patients

Medicine and Pharmacology, Oncology and Oncogenics

Not displayed online.

Please leave your comment to this article below.

Mathematical equations can be typed in either LaTeX formats \\[ ... \\] or $$ ... $$, or MathML format <math> ... </math>. Try the LaTeX or MathML example.

Type equation:

Preview:

Copy equation into message below

Close menu

Please click a symbol to insert it into the message box below:

Please enter the link here:

Optionally, you can enter text that should appear as linked text:

Copy link into message below

Close menu

Please enter or paste the URL to the image here (please only use links to jpg/jpeg, png and gif images):

Copy image into message below

Close menu

Type author name or keywords to filter the list of references in this group (you can add a new citation under Bibliography):

No existing citations in Discussion Group

Wikify editor is a simple editor for wiki-style mark-up. It was written by MDPI for Sciforum in 2014. The rendering of the mark-up is based on Wiky.php with some tweaks. Rendering of mathematical equations is done with MathJax. Please send us a message for support or for reporting bugs.

Close menu

Please declare any conflicts of interest you may have with this paper, financial or otherwise.

I do not have a conflict of interest

I would like to declare a conflict of interest

Display my name on the website

Captcha

Renew

I accept the following conditions:

Comments must follow the standards of professional discourse and should focus on the scientific content of the article. Insulting or offensive language, personal attacks and off-topic remarks will not be permitted. Comments must be written in English. Preprints reserves the right to remove comments without notice. Readers who post comments are obliged to declare any competing interests, financial or otherwise.

* All users must log in before leaving a comment

Notify me about updates to this article or when a peer-reviewed version is published.

Limited Local Clinical Trials for the New Cancer Treatment Technology Karanahan for Patients with Advanced Breast Cancer

Abstract

Keywords

Subject

Comments (0)